

MAY 21, 2025 BOARD MINUTES



GOVERNING BOARD MEETING MINUTES

Joint San Francisco Health Authority & San Francisco Community Health Authority Governing Board Minutes

May 21, 2025 (11:30 am to 2:00 pm)

Board Attendance. In attendance were the following board members: Abigail Alderson, Eddie Chan, PharmD, Norlissa Cooper, PhD, MSN, MBS, RN, Steven Fugaro, MD, Deneen Hadley, Johanna Liu, PharmD, Roland Pickens, MHA, FACHE, Adina Safer, Daniel Tsai, Joseph Woo, MD, and Jian Zhang, DNP, MS, FNP-BC.

Recused from the Closed Session: Eddie Chan, PharmD, Joseph Woo, MD, and Jian Zhang, DNP, MS, FNP-BC.

Absent: Juthaporn Chaloiecheep

Guests: The following were guests at the meeting:

- Michael Forster, FSA, MAAA, Consultant, Wakely
- James Reilly, SFHP external counsel from Epstein, Becker, and Green.
- Linnea Koopmans, CEO, Local Health Plans of California
- Welcome. Steven Fugaro, MD, Chair, opened the meeting and welcomed everyone. There were no public comments and Dr. Fugaro adjourned to Closed Session.

2. SFHP D-SNP Update.

This item was discussed in Closed Session.

The Board resumed in Open Session. Board members that recused themselves from the Closed Session joined the Open Session. Dr. Fugaro introduced Linnea Koopmans, CEO, Local Health Plans of California. He stated she will present State and Federal budget and policy updates during agenda item #7, CEO Report.

- 3. Report on Closed Session Action Items. Dr. Fugaro reported that the SFHP Governing Board approved the Dual Eligibles Special Needs Plan (D-SNP) bids for submission to the Centers for Medicare and Medicaid Services (CMS).
- 4. Board Business Appoint Daniel Tsai, Director of San Francisco Department of Public Health to the Governing Board. Dr. Fugaro introduced Daniel Tsai, who was appointed to the Director of Public Health for the City and County of San Francisco in February 2025. The San Francisco Ordinance and state law in the Welfare and Institutions Code authorizes this position or their designee to have a seat on the Governing Board. This seat was previously held by Dr. Grant Colfax. Dr. Fugaro stated SFHP was honored to welcome Mr. Tsai to the SFHP Governing Board and requested a nomination.

Motion to appoint Daniel Tsai to the Governing Board: Adina Safer

Second: Eddie Chan, PharmD.

The motion passed unanimously.

5. Consent Calendar. Dr. Fugaro introduced the items under the Consent Calendar and stated that the Board may request to remove any of the items from the Consent Calendar for a full discussion. None were removed and the following items were presented for the Consent Calendar:

Dr. Fugaro will state the following items are requested to be approved under the Consent Calendar:

- a. Minutes from the March 19, 2025, Board Meeting
- b. Credentialing and Recredentialing Recommendations

There were no issues or questions about any of the items on the Consent Calendar.

Motion to approve the Consent Calendar: Deneen Hadley

Second: Johanna Liu, PharmD.

The motion passed unanimously.

6. Review and Approval of Unaudited Financial Statements and Investment Reports. Anne Price, Chief Finance and Strategy Officer, and Rand Takeuchi, Controller, presented the unaudited financial statements and investment income reports for the guarter ending March 31, 2025.

For the month of March 2025, margin was slightly unfavorable to budget by (\$0.7) million with a reported margin of \$2.3 million versus a budgeted margin of \$3.0 million. Drivers contributing to the unfavorable variance were unfavorable net medical expenses of (\$2.0) million, unfavorable net administrative expenses of (\$0.1) million, offset by favorable performance in investment income of \$1.4 million. Excluding pass-throughs, the Medical Loss Ratio (MLR) came in unfavorable at 93.4% compared to budget of 91.0%.

There were no issues or concerns raised with the unaudited financials or investment reports.

Motion to approve the unaudited quarterly financial statements and investment

reports: Abigail Alderson Second: Roland Pickens

The motion passed unanimously.

- 7. Member Advisory Committee (MAC) Report. Abigail Alderson, Co-Chair of MAC, provided a report from the April 9, 2025, MAC meeting.
- **8.** Chief Executive Officer's (CEO) Report. Yolanda R. Richardson provided the Board with highlights from her CEO Report.

Ms. Richardson and SFHP staff covered the following updates:

- Operational Updates from the Office of the CEO Ms. Richardson provided an overview of key SFHP updates, including monitoring and analyzing state and federal policy changes and potential impact on SFHP members.
- b. D-SNP Update Jenn Moore, COO, provided the Board with an overview of SFHP's efforts to prepare for the D-SNP launch.
- c. State and Federal Updates (Linnea Koopmans)

Ms. Richardson introduced Linnea Koopmans, CEO, Local Health Plans of California. Ms. Koopmans presented slides that provided updates on the State and Federal budget and policy updates that impact Medi-Cal managed care.

All items were for discussion only and no actions were taken by the Board.

9.	Adjourned. Dr. Fugaro adjourned the meeting.
	·
	Secretary/Treasurer

Joint San Francisco Health Authority & San Francisco Community Health Authority Governing Board May 21, 2025 Closed Session Meeting Minutes

1. San Francisco Health Plan (SFHP) D-SNP Update and Approval to Submit the CMS Bids

Yolanda R. Richardson introduced Jenn Moore, COO, Dr. Steve O'Brien, CMO, and Anne Price, Chief Finance and Strategy Officer, to provide the Board with an update on SFHP's Dual Eligibles Special Needs Plan (D-SNP) network strategy, model of care, Stars, and other implementation updates. Ms. Price introduced Michael Forster, a consultant with Wakely, the actuarial firm SFHP contracts with for the D-SNP pro forma and bids, who provided a detailed overview of the bids that will be submitted to the Centers for Medicare and Medicaid Services (CMS). After discussion with the Board, staff, and consultant, the Board did not have any issues or concerns. Ms. Price requested the Board to approve the bids.

Motion to approve the SFHP D-SNP bids for submission to CMS: Johanna Liu, PharmD. Second: Adina Safer

The motion passed unanimously.